ADMA Biologics Defends Against Short Report Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 27 2026
0mins
Should l Buy ADMA?
Source: stocktwits
- Demand Growth Trend: ADMA Biologics asserts that demand for its immune globulin therapy, Asceniv, has been steadily increasing over the past two years, supported by data from distributors and end users, indicating strong market confidence in the product.
- Stock Price Surge: Following the release of the short report, ADMA's stock jumped 9% in pre-market trading on Friday, reflecting investor optimism about the company's outlook despite external challenges.
- Sales Data Clarification: In response to Culper Research's claim that ADMA inflated Asceniv's sales by 40% to 76%, the company emphasized the accuracy of its sales data, reporting a 20% revenue growth for 2025, contrasting sharply with Culper's prediction of a 3% decline.
- Inventory Management Explanation: ADMA addressed concerns regarding channel stuffing by stating that distributor inventory levels are consistent with industry norms, and maintaining safety stock reflects normal supply dynamics rather than excessive buildup.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Under Investigation for Securities Fraud Allegations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, urging investors to seek additional information regarding their legal options.
- Revenue Growth Scrutiny: While ADMA Biologics reported a 20% revenue growth in 2025, allegations suggest this was achieved through a channel stuffing scheme to obscure declining demand, with actual revenues potentially declining by 3% without such practices.
- Stock Price Plunge: Following the release of a report by Culper Research that exposed these channel stuffing allegations, ADMA Biologics' stock price fell by 29% over two trading days, from $13.59 to $9.63 per share, indicating significant market concerns about the company's financial integrity.
- Legal Implications: Investors may have legal recourse, as BFA offers representation on a contingency fee basis, emphasizing their commitment to protecting investor rights, which could also impact ADMA's future financing capabilities.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ADMA Biologics
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud against ADMA Biologics, Inc., focusing on whether the company and its executives engaged in unlawful business practices that could lead to significant investor losses.
- Short Report Allegations: On March 24, 2026, Culper Research published a report alleging that ADMA's reported growth was fictitious, estimating a 3% revenue decline in 2025 instead of the reported 20% growth, indicating potential channel stuffing practices.
- Stock Price Volatility: Following the release of the short report, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share on March 24, 2026, reflecting market concerns over the company's financial health.
- Rating Downgrade Impact: Cantor Fitzgerald downgraded ADMA's rating on March 26, 2026, citing a lack of specific feedback in response to the short report, which led to a further decline in stock price by $1.34, or 13.91%, closing at $8.29 per share, indicating a further erosion of investor confidence.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ADMA Biologics
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud against ADMA Biologics, Inc., focusing on whether the company and its executives engaged in unlawful business practices that could lead to significant investor losses.
- Short Report Allegations: A short report published by Culper Research on March 24, 2026, alleges that ADMA's reported growth is fictitious, driven by a de facto channel stuffing scheme and an undisclosed related party distributor, estimating a 3% revenue decline in 2025.
- Stock Price Plunge Impact: Following the release of the short report, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share, a drastic decline that may undermine investor confidence and trigger further legal actions.
- Law Firm Background: Pomerantz LLP is a prominent securities class action firm with over 85 years of experience, dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, having recovered millions in damages for class members, showcasing its expertise in such cases.
See More
ADMA Biologics Shares Plunge 16% Amid Investigation
- Stock Price Drop: ADMA Biologics experienced a significant share price decline of over 16% on March 24, 2026, following a report by Culper Research that accused the company of channel stuffing and undisclosed related party distributors, undermining investor confidence.
- Investigation Launched: National shareholder rights firm Hagens Berman has initiated an investigation into ADMA to determine if the company violated federal securities laws, particularly regarding the compliance of its financial reporting, urging investors who suffered significant losses to submit their information to assist in the inquiry.
- Financial Transparency Issues: Culper Research reported a dramatic increase in ADMA's days sales outstanding (DSO) to 113 days as of the end of 2025, up from 43 days the previous year, indicating that the company may have inflated revenues by inducing distributors to stockpile products, thus affecting the accuracy of its financial statements.
- Analyst Downgrade: The market's swift reaction to Culper's allegations led to a downgrade of ADMA's analyst rating from overweight to neutral, further exacerbating investor concerns regarding the company's future financial health.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential securities fraud, as the reported 20% revenue growth in 2025 may have been artificially inflated through channel stuffing, indicating serious issues with the company's financial transparency.
- Revenue Manipulation Allegations: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allowed the company to inflate revenue figures; without this scheme, actual revenue would have declined by 3% in 2025, significantly undermining investor confidence.
- Stock Price Plunge: The news of the investigation caused ADMA Biologics' stock to drop 29% over two trading days, from $13.59 per share on March 23 to $9.63 per share on March 25, reflecting market concerns regarding the company's financial health and credibility.
- Legal Implications: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency basis, demonstrating the firm's proactive approach to addressing potential legal liabilities and protecting shareholder interests.
See More
US Stocks Performance Review and Outlook
- Employment Data Expectations: ADP is set to release employment data at 8:15 a.m. ET, with a consensus estimate of 39,000 new jobs in the private sector, which will provide a crucial indicator of economic health and could influence investor confidence and market trends.
- Retail Sales Growth: Retail sales figures are expected to be released at 8:30 a.m., with a general forecast of a 0.5% increase, a data point that will directly impact consumer spending and the outlook for economic recovery, potentially guiding a market rebound.
- Corporate Earnings Dynamics: Cal-Maine, Conagra, and Lamb Weston are scheduled to report earnings before the bell, with Cal-Maine's stock flat over the past three months, Conagra down 9%, and Lamb Weston showing no significant change, all of which will affect investor sentiment towards the food sector.
- Market Performance Review: In the first quarter, the Russell 2000 index rose by 0.58%, making it the best performer among major indices, while the S&P 500 and Nasdaq 100 fell by 4.63% and 5.98%, respectively, reflecting market volatility and cautious investor sentiment.
See More
ADMA Biologics Under Investigation for Securities Fraud Allegations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, urging investors to seek additional information regarding their legal options.
- Revenue Growth Scrutiny: While ADMA Biologics reported a 20% revenue growth in 2025, allegations suggest this was achieved through a channel stuffing scheme to obscure declining demand, with actual revenues potentially declining by 3% without such practices.
- Stock Price Plunge: Following the release of a report by Culper Research that exposed these channel stuffing allegations, ADMA Biologics' stock price fell by 29% over two trading days, from $13.59 to $9.63 per share, indicating significant market concerns about the company's financial integrity.
- Legal Implications: Investors may have legal recourse, as BFA offers representation on a contingency fee basis, emphasizing their commitment to protecting investor rights, which could also impact ADMA's future financing capabilities.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ADMA Biologics
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud against ADMA Biologics, Inc., focusing on whether the company and its executives engaged in unlawful business practices that could lead to significant investor losses.
- Short Report Allegations: On March 24, 2026, Culper Research published a report alleging that ADMA's reported growth was fictitious, estimating a 3% revenue decline in 2025 instead of the reported 20% growth, indicating potential channel stuffing practices.
- Stock Price Volatility: Following the release of the short report, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share on March 24, 2026, reflecting market concerns over the company's financial health.
- Rating Downgrade Impact: Cantor Fitzgerald downgraded ADMA's rating on March 26, 2026, citing a lack of specific feedback in response to the short report, which led to a further decline in stock price by $1.34, or 13.91%, closing at $8.29 per share, indicating a further erosion of investor confidence.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ADMA Biologics
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud against ADMA Biologics, Inc., focusing on whether the company and its executives engaged in unlawful business practices that could lead to significant investor losses.
- Short Report Allegations: A short report published by Culper Research on March 24, 2026, alleges that ADMA's reported growth is fictitious, driven by a de facto channel stuffing scheme and an undisclosed related party distributor, estimating a 3% revenue decline in 2025.
- Stock Price Plunge Impact: Following the release of the short report, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share, a drastic decline that may undermine investor confidence and trigger further legal actions.
- Law Firm Background: Pomerantz LLP is a prominent securities class action firm with over 85 years of experience, dedicated to fighting for the rights of victims of securities fraud and corporate misconduct, having recovered millions in damages for class members, showcasing its expertise in such cases.
See More
ADMA Biologics Shares Plunge 16% Amid Investigation
- Stock Price Drop: ADMA Biologics experienced a significant share price decline of over 16% on March 24, 2026, following a report by Culper Research that accused the company of channel stuffing and undisclosed related party distributors, undermining investor confidence.
- Investigation Launched: National shareholder rights firm Hagens Berman has initiated an investigation into ADMA to determine if the company violated federal securities laws, particularly regarding the compliance of its financial reporting, urging investors who suffered significant losses to submit their information to assist in the inquiry.
- Financial Transparency Issues: Culper Research reported a dramatic increase in ADMA's days sales outstanding (DSO) to 113 days as of the end of 2025, up from 43 days the previous year, indicating that the company may have inflated revenues by inducing distributors to stockpile products, thus affecting the accuracy of its financial statements.
- Analyst Downgrade: The market's swift reaction to Culper's allegations led to a downgrade of ADMA's analyst rating from overweight to neutral, further exacerbating investor concerns regarding the company's future financial health.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential securities fraud, as the reported 20% revenue growth in 2025 may have been artificially inflated through channel stuffing, indicating serious issues with the company's financial transparency.
- Revenue Manipulation Allegations: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allowed the company to inflate revenue figures; without this scheme, actual revenue would have declined by 3% in 2025, significantly undermining investor confidence.
- Stock Price Plunge: The news of the investigation caused ADMA Biologics' stock to drop 29% over two trading days, from $13.59 per share on March 23 to $9.63 per share on March 25, reflecting market concerns regarding the company's financial health and credibility.
- Legal Implications: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency basis, demonstrating the firm's proactive approach to addressing potential legal liabilities and protecting shareholder interests.
See More
US Stocks Performance Review and Outlook
- Employment Data Expectations: ADP is set to release employment data at 8:15 a.m. ET, with a consensus estimate of 39,000 new jobs in the private sector, which will provide a crucial indicator of economic health and could influence investor confidence and market trends.
- Retail Sales Growth: Retail sales figures are expected to be released at 8:30 a.m., with a general forecast of a 0.5% increase, a data point that will directly impact consumer spending and the outlook for economic recovery, potentially guiding a market rebound.
- Corporate Earnings Dynamics: Cal-Maine, Conagra, and Lamb Weston are scheduled to report earnings before the bell, with Cal-Maine's stock flat over the past three months, Conagra down 9%, and Lamb Weston showing no significant change, all of which will affect investor sentiment towards the food sector.
- Market Performance Review: In the first quarter, the Russell 2000 index rose by 0.58%, making it the best performer among major indices, while the S&P 500 and Nasdaq 100 fell by 4.63% and 5.98%, respectively, reflecting market volatility and cautious investor sentiment.
See More
